tbuckley/cabot-search huggingface dataset:
NCMP-18. POST-OPERATIVE NEUROLOGICAL DEFICIT /VASOSPASM AFTER CRANIOPHARYNGIOMA SURGERY: EVALUATION OF CAUSATIVE FACTORS AND PREVENTION
Authors: Mukesh Bisht, Manoj Phalak
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Referring to a rare post-operative complication associated with craniopharyngioma surgery, Vasospasm. A number of possible causative factors have been postulated, like tumour encasing vessel, handling of vessels during surgery, but none have been able to explain delayed complication. Thus, we have evaluated series of patients operated in a single centre, to look for the possible aetiology METHODS Patient’s data have been collected retrospectively in the past 4 year, from a single centre, and cases that developed post-operative neurological deficit/vasospasm, proven clinically and/or radiology were included. Of 116 patients operated 6 were found to have clinical deterioration, and were confirmed using transcranial Doppler and/or radiologically demonstrable vasospasm. Each case was analysed retrospectively, and relevant variables were studied. RESULTS Patients developed neurological deficit/vasospasm ranging from Post-operative day 2 to second week after surgery. 1 expired, 2 improved over time, and 3 had persisting deficits. On evaluation, fluid balance showed changes, with serum Sodium levels. However, change of status from high volume status to low volume status was seen in almost all. CONCLUSIONS Development of post-operative neurological deficit/vasospasm is usually a cumulative result of some intraoperative insult like vessel handling, which could be a predisposing factor, and various post-operative factors like change In volume status, serum electrolytes levels, hormone status levels. Most important of all is to have an early and low threshold level to diagnose it, as early detection and action may a significant and possibly preventable morbidity or mortality
Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Authors: D. Planchard, S. Popat, K. Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, T.S. Mok, M. Reck, P.E. Van Schil, M.D. Hellmann, S. Peters
Journal: Annals of Oncology (2019)
Manpower: Compendium of deliberate mistakes
Journal: BMJ (1986)

The HJSC chairman, Dr Peter Hawker opened question time by expressing concern over Mr Meacher's comments on decentralisation.His committee believed that central negotiations were vital for doctors and that it would be harmful if local authorities set their own local standards.Mr Meacher assured the committee that there would be no interference with national negotiations- indeed, a circular would be issued to health authorities requiring a
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
Authors: Scott R. Daigle, Sung Choe, Lynn Quek, Courtney D. DiNardo, Anthony Stein, Eytan M. Stein, Amir T. Fathi, Olga Frankfurt, Andre C. Schuh, Hagop M. Kantarjian, Vickie Zhang, Thomas Winkler, Paresh Vyas, Bin Wu
Journal: Blood (2019)
Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
Authors: Carlo Gambacorti-Passerini, Tim H Brümmendorf, Bjorn T. Gjertsen, Camille Abboud, Gianantonio Rosti, Elisabetta Abruzzese, Eric Leip, Andrea Viqueira, Valentín García Gutiérrez, Frank Giles, Andreas Hochhaus
Journal: Blood (2019)
The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy
Authors: Xiaoli Zhang, Tian Zhang, Xianbin Ma, Yajun Wang, Yi Lu, Die Jia, Xiaohua Huang, Jiucun Chen, Zhigang Xu, Feiqiu Wen
Journal: Asian Journal of Pharmaceutical Sciences (2019)

Tumor cells show acidic conditions compared with normal cells, which further inspires scientist to build nanocarrier responsive to tumor microenvironment (TME) for enhancing tumor therapeutic efficacy. Here, we report a pH-sensitive and biocompatible polyprodrug based on dextran-doxorubicin (DOX) prodrug (DOXDT) for enhanced chemotherapy. High-density DOX component was covalently decorated on the nanocarrier and the drug molecules could be effectively released in the acidic tumor tissue/cells, improving chemotherapy efficacy. Specifically, a dextran-based copolymer was preliminarily prepared by one-step atom transfer radical polymerization (ATRP); then DOX was conjugated on the copolymer component via pH-responsive hydrazone bond. The structure of DOXDT can be well-controlled. The resulting DOXDT was able to further self-assemble into nanoscale micelles with a hydration diameter of about 32.4 nm, which presented excellent micellar stability. Compared to lipid-based drug delivery system, the DOXDT prodrug showed higher drug load capacity up to 23.6%. In addition, excellent stability and smaller size of the nanocarrier contributed to better tissue permeability and tumor suppressive effects in vivo. Hence, this amphipathic DOXDT prodrug is promising in the development of translational DOX formulations, which would be widely applied in cancer therapy.
Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS
Authors: Kelda Gardner, Megan Othus, Carole M. Shaw, Pamela S. Becker, Anna B. Halpern, Paul C. Hendrie, Bart L. Scott, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Journal: Blood (2019)
Annals Graphic Medicine - Dr. Mom: Dinosaurs on Rounds
Authors: Grace E. Farris
Journal: Annals of Internal Medicine (2019)

Web Exclusives5 November 2019Annals Graphic Medicine - Dr. Mom: Dinosaurs on RoundsFREEGrace E. Farris, MDGrace E. Farris, MDMount Sinai School of Medicine, New York, New York (G.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0062 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Mount Sinai School of Medicine, New York, New York (G.E.F.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G18-0042.Author/Illustrator Information: Grace E. Farris, MD, is an assistant professor of medicine at Icahn School of Medicine at Mount Sinai and chief of hospital medicine at Mount Sinai West hospital in New York, New York. You can view her work at her Web site: www.farrisgrace.com.About Dr. Mom: In Dr. Mom, physician and cartoonist Grace Farris examines work–life balance while mothering and doctoring. Dr. Mom appears monthly in Annals Graphic Medicine at Annals.org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2019Volume 171, Issue 9Page: W48-W52KeywordsConflicts of interestDisclosureHospital medicineHospitalists ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
THE PSYCHOLOGICAL FACTORS IN THE AETIOLOGY OF CERTAIN SKIN DISEASES.*
Authors: A. W. WATT
Journal: British Journal of Dermatology (1947)

Journal Article THE PSYCHOLOGICAL FACTORS IN THE AETIOLOGY OF CERTAIN SKIN DISEASES. Get access A. W. WATT A. W. WATT Physician, Lady Chichester Hospital, Hove Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 59, Issue 1, 1 January 1947, Pages 13–20, https://doi.org/10.1111/j.1365-2133.1947.tb11253.x Published: 01 January 1947
ACTR-49. INITIAL EXPERIENCE WITH SCALP PRESERVATION AND RADIATION PLUS CONCURRENT ALTERNATING ELECTRIC TUMOR-TREATING FIELDS (SPARE) FOR GLIOBLASTOMA PATIENTS
Authors: Andrew Song, Michele Ly, Voichita Bar-Ad, Maria Werner-Wasik, Jon Glass, Nina Martinez, David Andrews, Kevin Judy, James Evans, Christopher Farrell, Wenyin Shi
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Standard of care for glioblastoma includes concurrent chemoradiation and maintenance temozolomide with electric tumor treatment fields (TTFields). Preclinical studies suggest TTFields and radiation treatment have synergistic effects. We report our initial experience evaluating toxicity and tolerability of scalp-preserving radiation with concurrent TTFields. METHODS We conducted a single arm pilot study. Adult patients (≥ 18 years old) with KPS ≥ 60 with newly diagnosed glioblastoma were included. All patients received concurrent scalp-preserving radiation (60 Gy in 30 fractions), standard temozolomide (75 mg/m2 daily), and TTFields (200 kHz; ≥ 18 hr daily). Maintenance therapy included standard temozolomide and TTFields. Radiation treatment was delivered through TTFields arrays. Our primary endpoint was safety and toxicity for concurrent TTFields with chemoradiation in newly diagnosed glioblastoma. RESULTS Here we report the first seven patients on the trial. Five were male, and 2 female, with median age 58 y/o (range 49–73). Median KPS was 90. Median follow-up was 5.2 months (range 1.4–11.2). MGMT status was unmethylated for 6 patients, and one unknown, and no IDH mutations. Four (57.1%) received gross total resection and three (42.9%) had subtotal resection. All patients completed concurrent chemoradiation plus TTFields without radiation or TTFields treatment interruption or discontinuation. There was no related Grade 3 or higher toxicity. Skin toxicity (erythema, dermatitis, pruritus) was noted in all patients, however, limited to Grade 1 or 2 which resolved spontaneously or responded to topical medications. All patients were alive at time of writing. Two (28.6%) patients had progression, of which one (at 9 months) continued TTFields and temozolomide with bevacizumab, while the other (at 4 months) discontinued TTFields and underwent re-resection with bevacizumab. CONCLUSIONS Concurrent TTFields with scalp-preserving chemoradiation is a safe and feasible treatment option with limited toxicity. Future randomized prospective trial is warranted to define therapeutic advantages of concurrent TTFields with chemoradiation.
EPID-29. THE INFLUENCE OF SOCIOECONOMIC FACTORS AND CANCER CARE RECEIVED AT DIFFERENT FACILITIES ON OUTCOME IN PATIENTS WITH GLIOBLASTOMA
Authors: Terry Li, Palak Patel, Janice Chou, Amie Patel, Sylvia Crispo, Minerva Utate, Sylvia Kurz
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Younger age and higher performance status are strong positive predictors of longer survival in patients with high-grade gliomas. In many cancers, disparities in race, gender, socioeconomic background, and immigration status were shown to influence outcome. Only few studies have investigated the impact of healthcare disparities in patients with glioblastoma, with conflicting results. We hypothesized that patient-specific and healthcare system-related factors influence the utilization of healthcare and impact outcome in glioblastoma patients. METHODS This is a retrospective observational study in glioblastoma patients receiving care at a NCI-designated Comprehensive Cancer Center (CCC) or a City Hospital (CH). Patient information including demographics, insurance status, molecular characteristics, treatment details, and survival was retrieved from the medical record. RESULTS 59 patients were included (CCC n=47, PCH n=12). There were 22 females and 37 males. Median age was 63.0 years at CCC, 54.0 years at CH (p = 0.023). The two groups significantly differed by race (p=0.004), insurance status (p&lt; 0.001), median income by zip code (p=0.015), extent of resection (p=0.001), receiving radiotherapy (p=0.014), and receiving chemotherapy (p&lt; 0.001). Median overall survival (mOS) was longer at CCC (17.9 months) versus at CH (4.4 months) (p=0.021). Univariate Cox regression analyses found significantly better survival for insured vs. uninsured patients (HR 0.035, 95% CI 0.002–0.611, p=0.022) and for married/domestic partnership (M/DP) vs. non-M/DP patients (HR 0.352, 95% CI 0.141–0.879, p=0.025). Care facility, race, income, and treatment received did not emerge as significant predictors. Multivariate analysis controlling for facility and age at diagnosis showed improved survival for M/DP versus non-M/DP patients (HR 0.267, 95% CI 0.103–0.691, p=0.006). CONCLUSION(S): Insurance status and marital status emerged as significant contributors to survival. They may serve as surrogate markers for socioeconomic class and social support. Differences in Cancer Care received at different facilities may influence outcome as well.
Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial
Authors: Wei Zhang, Liping Su, Lihong Liu, Yuhuan Gao, Quanshun Wang, Hang Su, Yuqin Song, Huilai Zhang, Jing Shen, Hongmei Jing, Shuye Wang, Xinan Cen, Hui Liu, Aichun Liu, Zengjun Li, Jianmin Luo, Jianxia He, Jingwen Wang, Owen A. O'Connor, Daobin Zhou
Journal: Blood (2019)
Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction
Authors: Daji Wang, Hongxia Duan, Jing Feng, Jianquan Xiang, Liqun Feng, Dan Liu, Xuehui Chen, Lin Jing, Zheng Liu, Dexi Zhang, Hongjun Hao, Xiyun Yan
Journal: Theranostics (2019)

The blood-brain barrier (BBB) dysfunction is an initial event of various neuroinflammatory diseases.However, the absence of reliable markers and mechanisms for BBB damage greatly limits the diagnosis and treatment of neuroinflammatory diseases.Soluble CD146 (sCD146) is mainly derived from vascular endothelial cells (ECs) and highly elevated in inflammatory settings.Based on a small cohort, our previous study showed that sCD146 is elevated in the cerebrospinal fluid (CSF) of multiple sclerosis (MS), which is accompanied with BBB damage.Nevertheless, whether sCD146 monitors and regulates the BBB dysfunction remains unknown.Methods: Coupled serum and CSF samples from patients with or without neuroinflammatory diseases were collected via multicenter collaborations.sCD146 was measured by sandwich ELISA using anti-CD146 antibodies AA1 and AA98, both of which were generated in our laboratory.The correlations between sCD146 and other clinical parameters or inflammatory factors were analyzed by Spearman's correlation coefficient analysis.The role of sCD146 on BBB function was examined in an in vitro BBB model.Results: Between July 20, 2011, and February 31, 2017, we collected coupled serum and CSF samples from 823 patients, of which 562 (68.3%) had neuroinflammatory diseases, 44 (5.3%) had remitting MS, and 217 (26.4%) had non-inflammatory neurological diseases (NIND).We found that sCD146 in CSF, but not in serum, is abnormally elevated in neuroinflammatory diseases (37.3 ± 13.3 ng/mL) compared with NIND (4.7 ± 2.9 ng/mL) and remitting MS (4.6 ± 3.5 ng/mL).Abnormally elevated CSF sCD146 is significantly correlated with the hyperpermeability-related clinical parameters of BBB and neuroinflammation-related factors.Moreover, CSF sCD146 shows higher sensitivity and specificity for evaluating BBB damage.Using an in vitro BBB model, we found that sCD146 impairs BBB function by promoting BBB permeability via an association with integrin αvβ1.Blocking integrin αvβ1 significantly attenuates sCD146-induced hyperpermeability of the BBB. Conclusion:Our study provides convincing evidence that CSF sCD146 is a sensitive marker of BBB damage and neuroinflammation.Furthermore, sCD146 is actively involved in BBB dysfunction.
Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia
Authors: Angela R. Smith, Gary J. Schiller, Gregory M Vercellotti, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Erica B. Esrick, David A. Williams, Weston P. Miller, Adrian Woolfson, Mark C. Walters
Journal: Blood (2019)
IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS
Authors: Michael Zhang, Stephanie Hilz, Michael Martin, Chibo Hong, Yao Yu, Saumya Bollam, Matthew Grimmer, Timothy Looney, Geoffrey Lowman, Gauri Ganpule, Joanna Phillips, Anny Shai, Susan Chang, Jennifer Clarke, Jennie Taylor, Nicholas Butowski, Nancy Ann Oberheim-Bush, Mitchel Berger, Manish Aghi, Shawn Hervey-Jumper, Mike McDermott, Philip Theodosopoulos, Hideho Okada, Joseph Costello
Journal: Neuro-Oncology (2019)

Abstract The design and evaluation of immunotherapies in IDH-mutant lower grade gliomas (LGG) is hindered by a poor understanding of the LGG T-cell repertoire. We present data on the temporal evolution, intratumoral spatial distribution, and prognostic value of the T-cell repertoire in IDH-mutant LGGs. We performed immunogenomic profiling using T-cell receptor beta-chain sequencing of 163 glioma and peripheral blood samples from 33 immunotherapy-naive glioma patients (22 astrocytomas, 11 oligodendrogliomas). T-cell repertoire evolution was analyzed in a subset of 26 patients (69 samples) with matched primary (WHO grade II) and recurrent (WHO grade II-IV) glioma samples. T-cell repertoire diversity was defined as the number of unique T-cell clonotypes by V-gene, J-gene, and CDR3 nucleotide sequences. Malignant transformed (Grade III or IV) recurrent gliomas demonstrated increased T-cell repertoire diversity compared to their patient-matched primary tumors (p=0.0023), but grade II recurrences did not show the same increased diversity (p=0.26). This increase in T-cell repertoire diversity was greater in patients who underwent transformation in the context of TMZ-associated hypermutation compared to spontaneously transformed counterparts (p=0.035). In grade II primary astrocytomas (n=17), T-cell repertoire diversity above the median (186 unique T-cell clonotypes per sample) was associated with worse transformation-free (HR=4.2, p=0.045) and overall survival (HR=6.4, p=0.025). Next, we evaluated intratumoral immune heterogeneity in 7 patients by sampling from up to 10 distinct and maximally-separated intratumoral sites per LGG (64 samples). Eighty-two to 96% of unique clonotypes within a given tumor were present only within a single sampled site. Despite this heterogeneity, six LGG patients harbored T-cell clonotypes present tumor-wide across all sampled sites within a given tumor. Ten of 24 (42%) tumor-wide T-cell clonotypes were enriched in the glioma compared to matched peripheral blood, suggesting glioma-specificity. Taken together, T-cell receptor profiling in LGGs may have utility both as a prognostic biomarker and to identify glioma-specific T-cells.
EU financial watchdog criticises lack of progress in tackling antimicrobial resistance
Authors: Rory Watson
Journal: BMJ (2019)

The European Union’s strategy to tackle antimicrobial resistance (AMR) has failed to deliver significant results, according to a new report by the European Court of Auditors.

In a report,1 published on 15 November, the auditors conclude that despite EU assistance to national authorities, there was “little evidence to date that the health burden of AMR has been reduced in the European Union.” …
Emergency Department Admissions for Child Sexual Abuse in the United States From 2010 to 2016
Authors: Jesse J. Helton, Jason T. Carbone, Michael G. Vaughn, Theodore P. Cross
Journal: JAMA Pediatrics (2019)

This study uses data from the US Nationwide Emergency Department Sample and the US Census Bureau to examine patterns and characteristics among children admitted to the emergency department for sexual abuse from 2010 to 2016.
Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Lower Incidence of Grades II-IV Acute Graft-Vs-Host Disease after Umbilical Cord Blood Transplantation
Authors: Ting Ting Fang, Xiang Wan, Xiaoyu Zhu, Baolin Tang, Kaidi Song, Guangyu Sun, Huilan Liu, Xinchen Fang, Zimin Sun
Journal: Blood (2019)
ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition
Authors: F.G. Valiente, N. Tarazona, V. Gambardella, Á Riffo-Campos, F. Papaccio, M. Cabeza-Segura, G. López-Rodas, A. Cervantes, L. Franco, J. Castillo
Journal: Annals of Oncology (2019)
Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
Authors: Caitlin Siebenaller, Madeline Waldron, Kelly Gaffney, Brian P. Hobbs, Ran Zhao, Marc Earl, Marina Feldman, Hetty E. Carraway, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Bhumika J. Patel, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2019)
Home Screening for Human Papillomavirus Falls Short in Initial Application, Remains Promising
Authors: Chailee Faythe Moss, Betty Chou, Jenell S. Coleman
Journal: JAMA Network Open (2019)

Rachel L. Winer, PhD, MPH; John Lin, BA; Jasmin A. Tiro, PhD; Diana L. Miglioretti, PhD; Tara Beatty, MA; Hongyuan Gao, MS; Kilian Kimbel, BA; Chris Thayer, MD; Diana S. M. Buist, PhD, MPH
Acute Non-specific Diarrhoea and Dysentery
Authors: H. M. R. Jones
Journal: BMJ (1947)

JOUR1ALpresent should constantly be minimal.Is it indeed certain that new pus does not form after drilling of a bone?With regard to dosage of penicillin: That advocated by Great Ormond Street does seem to be unnecessarily low.Presumably this is because the series was begun at a time when there was a dearth of the drug, and the dosage was continued because it was found to be adequate.It is a fact that immediate improvement occurred (i.e., within 24 hours) in the majority of the cases.Penicillin must obviously be given to infants by intermittent injection, and the fewer these are the better, provided that an adequate concentration be obtained and the best possible results, for trauma undoubtedly upsets infants and makes handling of them more difficult as regards feeding, etc.Mobilization does not really form a large part in the treatment recommended.It is rather a suggestion that complete immobiliza- tion is unnecessary, and that simple metbods are adequate in the acute stage.Certainly there would be little weight-bearing in tlie infant age group, and it is probable that the risk of pathological fracture is less than the dangers and difficulties invoived in plaster immobilization in infants.With regard to positive blood cultures: this may be rather a false percentage, for no doubt some difficulties were experienced in obtaining some or sufficient blood in all cases.This point is not made clear in the article.It would seem reasonable to accept, with reservations, the principles both of the Great Ormond Street and the Oxford series.It might be wise to use the Oxford meth9d in older patients with severe infections, while the Great Ormond Street technique seems certainly to be adequate in the less severe cases, and in all infants in whom operations should not be